Why the study?
Does pazopanib treatment improve outcomes in Japanese patients with relapsed soft tissue sarcoma?
Does pazopanib treatment improve outcomes in Japanese patients with relapsed soft tissue sarcoma?
Pazopanib shows efficacy differences among histologic types of soft tissue sarcoma in Japanese patients, with notable adverse events including pneumothorax and thrombocytopenia.
May inform histologic selection for pazopanib in relapsed STS; leaves open need for randomized confirmation.
There were apparent differences in the efficacy of pazopanib treatment among histologic types of STS. Pazopanib treatment is a new treatment option; however, adverse events like pneumothorax and thrombocytopenia, which did not occur frequently in the PALETTE study (pazopanib for metastatic soft-tissue sarcoma), should be taken into consideration. Cancer 2016;122:1408-16.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: